Baird analyst Eric Coldwell downgraded Science 37 to Neutral from Outperform with an unchanged price target of $5.75. The analyst says the shares are approaching proposed acquisition price. The company announced plans to be acquired by eMed at $5.75 per share.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SNCE:
- Science 37 to be Acquired by eMed, Expanding Access to Patients and Accelerating Enrollment
- Science 37 Receives Top Honors in Everest PEAK Matrix®
- Science 37 Holdings Inc trading halted, news pending
- Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
- Science 37 Holdings, Inc. Announces 1-for-20 Reverse Stock Split effective December 8, 2023
